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Abstract
Background: Many tumors are associated with decreased cellular immunity and elevated levels of prostaglandin E2 (PGE2),
a known inhibitor of CD4+ T cell activation and inducer of type-2 cytokine bias. However, the role of this immunomodulator
in the survival of T helper cells remained unclear. Since CD4+ T cells play critical roles in cell-mediated immunity, detail
knowledge of the effect tumor-derived PGE2 might have on CD4+ T cell survival and the underlying mechanism may,
therefore, help to overcome the overall immune deviation in cancer.
Methodology/Principal Findings: By culturing purified human peripheral CD4+ T cells or Jurkat cells with spent media of
theaflavin- or celecoxib-pre-treated MCF-7 cells, we show that tumor-shed PGE2 severely impairs interleukin 2 receptor cc
(IL2Rcc)-mediated survival signaling in CD4+ T cells. Indeed, tumor-shed PGE2 down-regulates IL2Rcc expression, reduces
phosphorylation as well as activation of Janus kinase 3 (Jak-3)/signal transducer and activator of transcription 5 (Stat-5) and
decreases Bcl-2/Bax ratio thereby leading to activation of intrinsic apoptotic pathway. Constitutively active Stat-5A (Stat-
5A1*6) over-expression efficiently elevates Bcl-2 levels in CD4+ T cells and protects them from tumor-induced death while
dominant-negative Stat-5A over-expression fails to do so, indicating the importance of Stat-5A-signaling in CD4+ T cell
survival. Further support towards the involvement of PGE2 comes from the results that (a) purified synthetic PGE2 induces
CD4+ T cell apoptosis, and (b) when knocked out by small interfering RNA, cyclooxygenase-2 (Cox-2)-defective tumor cells
fail to initiate death. Interestingly, the entire phenomena could be reverted back by theaflavins that restore cytokine-
dependent IL2Rcc/Jak-3/Stat-5A signaling in CD4+ T cells thereby protecting them from tumor-shed PGE2-induced
apoptosis.
Conclusions/Significance: These data strongly suggest that tumor-shed PGE2 is an important factor leading to CD4+ T cell
apoptosis during cancer and raise the possibility that theaflavins may have the potential as an effective immunorestorer in
cancer-bearer.
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Introduction
Prostaglandins are lipid molecules regulating numerous pro-
cesses including modulation of immune function [1–3]. PGE2 is
produced by many different cell types, including malignant cells,
and is known to contribute to cellular immune suppression in
cancer patients [4,5]. On the other hand, deletion of the respective
prostaglandin receptors leads to reduced carcinogenesis and
enhanced antitumor immunity [6].
Current paradigms suggest that CD4
+ T cells play critical roles in
the optimal induction and maintenance of clinically beneficial tumor
immunity [7,8]. These cells prime CTL-mediated antitumor
responses [9] by preventing activation-induced cell death and
functioning as antigen-presenting cells for CTLs to preferentially
generate immune memory cells [10,11]. CD4
+ helper T cells also
induce CD8
+ cytotoxic T cell responses through dendritic cell
activation by CD40/CD40L interactions [12] and determine the
magnitude and persistence of such responses as well as CD8
+ Tc e l l
infiltration of tumors [13]. Therefore, in order to establish itself, a
growing tumor tries to overpowerCD4
+ T cells. It hasbeen reported
that both human patients and experimental animals with advanced
cancer often exhibit a poorly functioning immune system [14-19].
There is evidence of increased apoptosis among CD4
+ Tc e l l si n
peripheral blood lymphocytes from cancer patients and animal
models [20,21]. Understanding the mechanisms of tumor-induced
CD4
+ T cell apoptosis as well as its amelioration by any biological
response modifier is, therefore, of high importance from the point of
view of amelioration of tumor-induced immuno-suppression.
Chemnitz et al. [22] have reported impairment in CD4
+ T cell
activation in cancer patients by PGE2. Tumor-shed PGE2 has been
found to mediate profound alteration in cytokine balance in the
cancer microenvironment and thereby contributing to T cell
suppression in cancer patients [23,24]. In fact, IL2 and IL2Rcc
gene expression, that play crucial role in T cell proliferation,
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inducedsuppression [26,27],possibly throughtheinhibitionofearly
events in T-cell signaling that include calcium influx and
phosphatidylinositol breakdown [28,29]. Moreover, PGE2 has been
reported to down-regulate Jak-3 protein, which associates with
IL2R, in T cells [26,27]. This reduction in Jak-3 resulted in
impaired phosphorylation and DNA binding activity of Stat-5
[26,27]. Because Jak-3 is critical to IL2-dependent signaling and
proliferation, its sensitivity to PGE2 may make it a prime target for
suppressing IL2-dependent cell cycle progression in T cells. It is well
accepted that Jak-mediated survival signals modulateBcl-2 familyof
anti-apoptotic proteins [30]. Studies with Jak-3 deficient mice have
showed down-regulation of Bcl-2 in CD8
+ T cell population in
thymus [31]. Other reports have demonstrated correlation between
loss in Bcl-2 expression and death of T cells [32].
Interestingly, although PGE2 has been implicated in the
increase or the acceleration of the programmed cell death process
of immature CD4
+CD8
+CD3
+ thymocytes in culture [33],
CD4
+CD8
+ thymocytes inside the thymus in mice [34], and
favors Th2-like cytokine secretion profiles in murine and human
CD4
+ T cells [35], there is no detail report on its effect on CD4
+ T
cell survival, if any, and the underlying mechanism. Since these
helper T cells play critical roles in the optimal induction and
maintenance of clinically beneficial tumor immunity [7,8], here we
address the role tumor-derived PGE2 might have on CD4
+ T cell
survival. Using exclusively primary human CD4
+ T cells we found
a correlation between over-expression of PGE2 in tumor cells and
tumor-induced CD4
+ T cell apoptosis. Inhibitory effects of tumor-
shed PGE2 were in fact dependent on impairment of IL2Rcc
signaling that lead to down regulation of IL2Rcc, reduced
phosphorylation of Jak-3 and Stat-5A and decreased expression
of pro-survival protein Bcl-2. Additionally, we demonstrated
release of cytochrome c from mitochondria to cytosol and
activation of caspase cascade. It was interesting to note that
theaflavins, the black tea polyphenols, protected IL2Rcc signaling
in CD4
+ T cells from tumor-secreted PGE2 insult by inhibiting
Cox-2 expression and subsequent PGE2 release from tumor cells.
That these effects occurred in the absence of tumor cell-T cell
contact negated the possibility of tumor contact-dependent CD4
+
T cell apoptosis and highlighted PGE2 as an important mediator
of impaired cellular immunity in patients with cancer.
There are ample evidences demonstrating the biological impact
of theaflavins. These bioactive flavonoids of black tea have been
reported to induce cell growth inhibition and apoptosis in a variety
of cancer cells [36–38] Theaflavins also exert a plethora of
beneficial effects on the cardiovascular system [39] and play a role
in decreased intestinal cholesterol absorption thereby being
responsible for lowering blood-cholesterol [40]. Antioxidative
properties of theaflavins are manifested by their ability to inhibit
free radical generation, scavenge free radicals and down-regulate
the activity of pro-oxidative enzymes [41]. They can also influence
activation of transcription factors such as NFkappaB or AP-1 [41].
However, there was hardly any report suggesting the immuno-
protective effect of theaflavins. Our findings signify that theaflavins
can be a possible therapeutic agent with a strong immunomod-
ulatory effect and therefore, in future can be used alone or in
combination with tumoricidal drugs to treat patients with cancer.
Results
Cell-free tumor supernatant leads to CD4
+ T cell
depletion by inducing apoptosis
When purified CD4
+ T cells were cultured in the presence of
cell-free breast cancer cell (MCF-7) supernatants (Fig. 1A), a
situation mimicking the tumor-bearing condition in which tumor-
shed mediators influence the circulating CD4
+ T cell repertoire,
increase in the percent of dead CD4
+ T cell (43.2%) in comparison
to control (7.2%) was recorded. Interestingly, when these T cells
were co-incubated with theaflavin-pretreated tumor culture
supernatants, significant protection from tumor-induced death
was observed in a theaflavin-dose-dependent manner, the
optimum effect being at 25 mg/ml theaflavins (11.6% dead cells),
beyond which no further significant change could be obtained
(Fig. 1A). Subsequent studies were, therefore, carried out with this
dose of theaflavins.
Depletion in CD4
+ T cell populations by tumor supernatant
prompted us to investigate the underlying cause. Next, to assess the
mode of cell death,we used three-colorflowcytometry (FITC-CD4,
PE-Annexin-V and 7AAD). Results of Figure-1B depict that while
cell-freeMCF-7 supernatants causedapoptosisto human peripheral
CD4
+ T cells (38.4% in supernatant-treated cells and 5.5% in
control) as well as Jurkat cells (42.5% in supernatant-treated cells
and 8.2% in control), theaflavins furnished protection to them.
Interestingly, theaflavins did not change CD4
+ cell numbers
significantly when applied directly to control CD4
+ T cells (Fig. 1B).
Figure 1. Cell free tumor supernatant leads to CD4
+ T cell
depletion by inducing apoptosis. A, Purified human peripheral
CD4
+ T cells were cultured in the presence of media alone or cell-free
MCF-7-spent media (6theaflavins, doses from 6.25 mg/ml to 50 mg/ml).
After 48 hours, viable cell numbers were scored by Trypan Blue
exclusion method. B, Graphical representation of percent apoptosis of
CD4
+ T cells (left panel) and Jurkat T cells (right panel). CD4
+ T cells
labelled with Annexin V-PE and 7AAD were analyzed flow cytome-
trically. Annexin V/7AAD-positive cells were regarded as apoptotic cells.
Values are mean6S.E.M. of five independent sets of experiments.
doi:10.1371/journal.pone.0007382.g001
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All the reactions so far defined occurred independent of direct
contact of CD4
+ cells with tumor cells or even proximity thereby
pointing towards the possibility of the presence of tumor-shed
soluble immunosuppressors in the supernatant. Our search
revealed a significant increase in PGE2 in tumor supernatant in
a time-dependent manner with a maximum at 72 hours of
continuous culture while media from theaflavins-treated MCF-7
cells contained significantly lower levels of this immunosuppressor
(Fig. 2A). Moreover, percent CD4
+ cell apoptosis was positively
correlated (r=0.964) with the PGE2 level of individual superna-
tant (Fig. 2B), whereas theaflavin-pre-treated tumor supernatants
failed to induce significant death. Importantly, insertion of Cox-2-
siRNA in tumor cells blocked the increase in PGE2 in cell-free
tumor supernatant overtime (Fig. 2A). This suggested inhibition in
the generation and/or release of PGE2 that resulted in lesser
killing of CD4
+ cells than untreated ones (Fig. 2B). All these data
confirmed the role of Cox-2-derived PGE2 in tumor-induced
CD4
+ T cell killing. These results prompted us to explore the
possibility of theaflavins to inhibit PGE2 production in tumor cells.
Results of Figure 2 indeed depicted that theaflavin-treated tumor
cells secreted significantly low level of PGE2 (Fig. 2A) that
displayed lesser CD4
+ cell killing (Fig. 2B)
PGE2 perturbs IL2Rc-signaling events in CD4
+ T cells
It is known that IL2 is essential for T cell homeostasis and
activation for which it depends on IL2Rcc signaling [42,43]. Thus,
cc down regulation, if any by tumor-secreted PGE2, may fail to
support T cells that then become susceptible to apoptotic death
[43]. In our experimental model, we observed a marked decrease
in the surface expression (Fig. 3A) as well as total amount (Fig. 3B)
of IL2Rc chain in CD4
+ T cells that were co-incubated with
tumor supernatants (Fig. 3A). Receptor expression in CD4
+ T cells
could be efficiently restored back to normal level by theaflavin-
treatment of tumor cells (Fig. 3A and 3B).
It has been shown that Jak-3 is required to activate IL2R
pathway for T cell proliferation [44] and loss of Jak-3 expression
or kinase activity results in impaired activation of the IL2R
signaling pathway [45]. Moreover, it is acknowledged that
IL2Rcc is the primary mediator of cytokine signaling and
activates Jak-3/Stat-5 signaling cascade [46] by Jak/Stat
phosphorylation and subsequent translocation of phospho-Stat
to nucleus [47]. We observed that, of the Jak proteins and
associated Stat proteins, phosphorylations of Jak-3 and Stat-5
were down regulated in CD4
+ T cells (Fig. 3B–C) by tumor-shed
PGE2 (Fig. 2A), which could be ameliorated by pre-treatment
of the tumor cells with theaflavins (Fig. 3B–C). To test whether
Stat-5 was phosphorylated by Jak-3, we co-immunoprecipitated
Stat-5 with anti-Jak-3 antibody, and the immunopurified proteins
were then Western-blotted with anti-phospho-Stat-5 antibody.
Results of Figure 3D showed that tumor supernatant substantially
reduced association of phospho-Stat-5 with Jak-3 in CD4
+ T
cells. Perturbation in phospho-Stat-5 nuclear translocation
activity was also observed in tumor-exposed CD4
+ Tc e l l si n
comparison to its untreated counterparts (Fig. 3E). Perturbation
in phospho-Stat-5 nuclear translocation activity was also observed
in tumor-exposed CD4
+ T cells in comparison to its untreated
counterparts (Fig. 3E). Interestingly, when CD4
+ cells were
cultured in presence of theaflavin-pretreated tumor cell superna-
tants, significant protection towards IL2Rcc/Jak-3/Stat-5 signal-
ing i.e., up-regulation of cc expression, Jak-3/Stat-5 association
and phosphorylation as well as nuclear localization of Stat-5
(Fig. 3B–E), was observed in CD4
+ T cells, which offered them
relive from the apoptotic insult that was observed with untreated
tumor supernatant (Fig. 2B).
Stat-5A transfection confers resistance to CD4
+ T cells
from tumor-induced death
After confirming the Stat-5-mediated pathway as the major
pathway in tumor-induced CD4
+ T cell apoptosis, we undertook
two different approaches to identify the isoform(s) of Stat-5
involved since both Stat-5A and Stat-5B isoforms play critical role
in Bcl-2 induction in T cells. Results of Figure-4A depict that
PGE2 present in cell-free tumor supernatant (Fig. 2A) significantly
inhibited the phosphorylation of Stat-5A (Fig. 4A, left panel) but not
that of Stat-5B (Fig. 4A, right panel). In this situation too, prior
treatment of the tumor cells with theaflavins could bring back the
phosphorylation status of Stat-5A to normal level in CD4
+ T cells
(Fig. 4A, left panel).
To further confirm the role of two Stat-5 isotypes in tumor-
induced CD4
+ T cell demise, Jurkat T cells were over-expressed
with wild-type Stat-5A/Stat-5B, C-terminal truncated dominant
Figure 2. Tumor-shed PGE2 is responsible for CD4
+ T cell apoptosis. A, Tumor-secreted PGE2 over time in cell-free spent media of MCF-7 cells
(control (#), Cox-2-siRNA-transfected (D) or theaflavin-treated (N) was determined by ELISA. B, Percent CD4
+ T cell death (Annexin-V-PE
+/7AAD
+),
induced by the spent media as described in Fig. 2A, was plotted over time. Values are mean6S.E.M. of three independent sets of experiments.
doi:10.1371/journal.pone.0007382.g002
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Stat-5A (Stat-5A1*6) genes (Fig. 4B) and then incubated with
tumor-culture supernatants. Multiple experiments demonstrated
that unlike wild-type cells, constitutively active Stat-5A1*6-
transfected cells were only minimally affected, with an average
of only 6–10% of the transfected cells succumbing to a tumor-
supernatant-induced apoptotic death and theaflavins were able to
protect them further (Fig. 4B). On the other hand, when dominant
negative Stat-5A713 was introduced into Jurkat T cells, this protein
rendered these cells more susceptible to tumor-induced death that
could not be successfully prevented by theaflavin-administration.
In contrast, theaflavins were able to protect Stat-5B718-transfected
Jurkat T cells from tumor-induced death (Fig. 4B). When wild-type
Stat-5A was introduced into these cells, it was able give protection
from tumor-induced death, by itself or in the presence of
theaflavins (Fig. 4B). All these results strongly reconfirm our
hypothesis that Stat-5A protects CD4
+ T cells from tumor-induced
apoptosis and theaflavins utilize this isoform of Stat-5 to assert its
protective effect.
Tumor-shed PGE2 indulges a shift from pro-survival to
pro-apoptotic environment in CD4
+ T
It is acknowledged that the regulation of both pro- and anti-
apoptotic Bcl-2 family proteins is dependent upon the IL2Rc
chain signals [43] involving Jak-3/Stat-5 cascade. Thus, cc down
regulation and inhibition of Jak-3/Stat-5A signaling by PGE2
present in the tumor supernatant, as obtained here, may fail to
support sustained Bcl-2 expression, leading to CD4
+ T cells
susceptibility towards apoptotic death. To verify this hypothesis,
we examined the expression levels of anti-apoptotic Bcl-2 and pro-
apoptotic Bax proteins in CD4
+ T cells. Results of Figure-5A
depict that tumor insult down-regulated Bcl-2 and up-regulated
Bax thereby lowering the Bcl-2:Bax ratio and creating a pro-
apoptotic environment in these helper cells. Moreover, the
expression of Xiap (X-linked inhibitor of apoptosis protein), a
member of the inhibitor of apoptosis family of proteins, was
diminished in these T cells treated with tumor supernatant
(Fig. 5A), making them more susceptible to execution by caspases,
as Xiap is known to inhibit caspases-3, -7 and -9 [48].
Figure 3. Tumor-PGE2 perturbs IL2Rcc signaling events in CD4
+ T cells. Purified human CD4
+ T cells, cultured in the presence of media alone
or cell-free MCF-7-spent media (6theaflavins), were (A) subjected to flow cytometric analysis to determine the surface levels of IL2Rcc, or lysed for
Western blotting of (B) IL2Rcc, (C) tyrosine phosphorylated Jak-1/Jak-3 and (D) tyrosine phosphorylated Stat-1/Stat-2/Stat-3/Stat-4/Stat-5/Stat-6 using
specific antibodies. (E) Jak-3/Stat-5 complexes were immunopurified with anti-Jak-3 antibody from CD4
+ T cell lysates. The immunopurified proteins
were subjected to Western blot analysis to confirm association of Jak-3 with Stat-5. (F) Nuclear fractions from CD4
+ T cells were Western blotted using
anti-phospho-Stat-5 antibody to determine nuclear translocation of Stat-5. a-Actin and Histone H1 were used as internal loading controls for cytosol
and nuclear fractions, respectively.
doi:10.1371/journal.pone.0007382.g003
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transfected with Bcl-2 construct. Multiple experiments demon-
strated that although control T cells were highly sensitive to tumor
supernatant, with an average of 42% of Jurkat cells testing positive
for apoptosis, Bcl-2-transfected cells were only minimally affected,
with an average of only 12% of the transfected cells succumbing to
a tumor supernatant-induced apoptotic death (Fig. 5B). These
results led us to ask the question whether over-expression of Xiap
would also make these cells more resistant to tumor-induced
death. In fact, when these cells were over-expressed with Xiap
gene, less killing was observed (Fig. 5B).
It is appreciated that the increase in Bax may cause
mitochondrial trans-membrane potential loss that results in the
release of cytochrome c in CD4
+ T cell cytosol leading to
activation of caspase cascades and apoptosis [49]. The experiment
depicted in Figure-5A clearly illustrates that culturing CD4
+ T
cells with MCF-7 cell free supernatant, a significant increase in
cytochrome c level in cytosol was observed while in unexposed
CD4
+ T cell cytosol it was minimally detected (Fig. 5A). Infact, in
the downstream, substantial activation of caspase-3 was observed
in supernatant-treated CD4
+ T cells. These results indicate a total
impairment in IL2Rcc survival signaling in CD4
+ T cells by
tumor-secreted PGE2. All these factors were restored back to their
original levels up on prior treatment of tumor cells with theaflavins
(Fig. 5A) thereby protecting CD4
+ cells from tumor-induced
apoptosis.
Re-confirmation of PGE2 as the molecule behind tumor-
induced perturbation in CD4
+ T cell survival signaling
Finally, to re-confirm the role of tumor-shed PGE2 in
materialising the CD4
+ T cell killing effect of tumor, we undertook
two approaches. In the first approach, when CD4
+ T cells were
cultured in presence of supernatants of tumor cells pre-treated
with celecoxib or tranfected with Cox-2-siRNA. These treatments
caused marked inhibition not only in Cox-2 expression (Fig. 6A,
upper panel) but also in PGE2 production by the tumor cells (Fig. 6A,
lower panel) and significant protection for the IL2Rcc signaling in
CD4
+ T cells i.e., up-regulation of cc expression, Jak-3/Stat-5
phosphorylation and increase in Bcl-2 level (Fig. 6B, upper panel),
which offered these T cells relive from the apoptotic insult (Fig. 6B,
lower panel). These findings were again validated in the second
approach, in which treatment of CD4
+ T cells with purified PGE2
Figure 4. Stat-5A transfection confers resistance to CD4
+ T cells from tumor-induced death. A, Stat-5A (left panel) and Stat-5B (right panel)
isoforms were immunoprecipitated from cell lysates using specific antibodies and then Western blotted with anti-phospho-tyrosine or anti-Stat-5A/
Stat-5B antibodies to determine phosphorylation status of specific proteins. B, Jurkat T cells were transfected with control vector, wild-type Stat-5A/
Stat-5B, C-terminal truncated Stat-5A713/Stat-5B718 or constitutively active Stat-5A1*6 genes and were cultured in the presence of media alone or MCF-
7 spent media (6theaflavins) for 48 h. Percent cell death (Annexin-V-PE
+/7AAD
+) was determined flow cytometrically. Values are mean6S.E.M. of
three independent sets of experiments.
doi:10.1371/journal.pone.0007382.g004
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induced apoptosis (Fig. 6B, lower panel). Results from these two
approaches well confirmed the importance of tumor-shed PGE2 in
impairment of IL2Rcc survival signal in CD4
+ T cells that
culminated to apoptosis. Above data also signify that normaliza-
tion of this signaling pathway may be the mechanism by which
theaflavins prevent tumor-induced caspase-3-dependent CD4
+ T
cell apoptosis.
Discussion
A functional immune system is a potential barrier to tumor
development and progression. To evade immune mechanisms,
many tumors release immunosuppressive factors that attain high
concentration in situ and inhibit cell-mediated effector function.
Suppression of immune responses, coupled with superior growth
kinetics of tumor cells, enable the neoplasm to surpass the control
capacity of the host, leading to progressive decreases in cell-
mediated anti-tumor responses and accelerated disease [50].
Although the immune system possesses the means to respond to
cancer, it often fails to control the spread of malignancy. The fact
that numerous laboratories, including our own, find that T
lymphocytes undergo the physiological changes associated with
apoptosis following co-culture with various cancer cell lines, lends
support to the notion that it is the cancer cells themselves that
induce lymphocyte death [14,27]. Recent studies suggest that
human carcinoma cells of various origins can activate apoptosis in
lymphocytes interacting with the tumor in vivo and in vitro [51–53].
This tumor-induced apoptosis of lymphocytes may have important
implications for the success of therapeutic regimens, including
vaccination strategies [54].
Ample evidence suggests that CD4
+ T cells facilitate the
activation and development of anti-tumor responses of CD8
+ T
cells by enhancing clonal expansion at the tumor site, preventing
activation-induced cell death and functioning as antigen-present-
ing cells for CTLs to preferentially generate immune memory cells
[10]. CD4
+ T cells assist CD8
+ T cell priming via the engagement
of CD40-ligand (CD154) on CD4
+ T cells and CD40 expressed on
DC [55–57]. This interaction results in the activation and
maturation of DC, making them competent to stimulate antigen-
specific CD8
+ T cell responses [58]. It is important to note that
primary CD8
+ T cell responses to nonmicrobial antigens, as in
case of cancer, display an absolute dependence on CD4
+ T cell
help [59,60]. In this regard, our understanding of the importance
of CD4
+ T cells in orchestrating immune responses has grown
dramatically over the past decade [10]. Here we aimed at
elucidating the mechanisms of the tumor-induced suppression of
such ‘T-cell help’ and its amelioration by theaflavins.
It has been demonstrated that several carcinoma cell lines
produce soluble factors that inhibit T cell proliferation. Because
tumor-induced apoptosis of lymphocytes may be mediated by an
array of death receptors co-expressed on T cells or by tumor-
derived soluble factors, it is important to characterize those
intracellular events that may be potential targets for therapeutic
intervention to minimize T cell apoptosis since if the immune
system of cancer patient is persistently compromised, the success of
any kind of therapy would be limited unless the immune system
can be appropriately stimulated.
PGE2 has been implicated as a potential inhibitor of T cell
function in the context of malignant disease [61,62]. Elevated levels
of PGE2 have also been found in patients with Hodgkin’s
lymphoma, which is suggested to be partially responsible for
decreased cellular immune function in these patients [4,5]. Another
report confirmed that tumor over-expression of PGE2 via the
elaboration of Cox-2 directly blocks patient’s defence mechanism
against cancer and promote cancer growth [63]. It is well known
that PGE2 has diverse effects on CD4
+ T cells leading to inhibition
of T cell activation [64]. Albeit the outcome of PGE2-signaling is
well established, the molecular mechanisms involved are still not
completely understood. The present study was designed to
determine the potential mechanisms of tumor-derived PGE2
leading to CD4
+ T cell apoptosis. We exclusively used primary
human CD4
+ T cells to achieve more physiologic conditions
compared with cell line models defective in key enzymes of T cell
signaling [65]. Our study demonstrated the presence of Cox-2
derived PGE2 in tumor supernatant and that the effect of tumor
supernatant on CD4
+ T cells bore remarkable similarities with the
effects of PGE2 exposure on these cells. Analysis of data revealed
Figure 5. Tumor-shed PGE2 indulges a shift from pro-survival to pro-apoptotic environment in CD4
+ T cells. A, Purified CD4
+ T cells
were cultured in the presence of media alone or MCF-7 spent media (6theaflavins) and cell lysates (for the determination of Bcl-2 and Bax) as well as
cytosolic fractions (for cytochrome c release, Xiap expression and caspase-3 cleavage) were Western blotted using specific antibodies. a-Actin was
used as internal loading control. B, Jurkat T cells, wild type as well as Bcl-2 or Xiap transfected, were incubated with media alone or MCF-7-spent
media for 48 h. Percent cell death was determined flow cytometrically. Values are mean6S.E.M. of four independent sets of experiments in each case.
doi:10.1371/journal.pone.0007382.g005
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of the major pathways for survival and activation of CD4
+ T cells.
This interference affected cc expression, Jak-3/Stat-5 phosphory-
lation and Bcl-2 level suggesting an inhibition of early IL2Rcc-
mediated signaling events in CD4
+ cells. We showed that PGE2
leads to down-regulation of IL2Rcc expression and Jak-3
phosphorylation thereby inactivating the most proximal events of
IL2Rcc signaling. Inability of externally added IL2 to overcome
tumor-PGE2 effect indicated that IL2 deprivation is not the primary
cause of CD4
+ cell death in our system.
Alternatively, theaflavins, which inhibited Cox-2 expression and
subsequent PGE2 production in tumor cells, efficiently ameliorat-
ed tumor-induced impairment of IL2Rcc signaling. Recovery of
Jak/Stat signaling also altered Bcl-2:Bax ratio in these helper cells
in favour of survival. These results are in contrary to those of
Kolenko et al. [26] who showed that in renal cancer, impairment in
IL2R signaling by PGE2 did not affect IL2-dependent induction of
Bcl-2. However, studies with Jak-3
2/2 knockout mice showing
impaired T cell development and severe down-regulation of Bcl-2
protein in T cell populations with moderate increase in Bax
expression [66,67] strengthened our findings. Interestingly, thea-
flavins offered better protection to T helper cells from tumor-
induced death in comparison to either celecoxib or Cox-2-siRNA
suggesting that along with PGE2, tumor-induced CD4
+ T cell
death might have other mediators that are independent of Cox-2
and inhibition of not only PGE2 but also those mediators by
theaflavins could be the cause behind observed immunoprotection
provided by these polyphenols.
In conclusion, our data provide direct evidence that tumor-
derived Cox-2-dependent PGE2 affects IL2Rcc-driven signals in
CD4
+ T cells by down-regulating IL2Rcc and inactivating Jak
resulting in impaired activation of downstream signals as shown by
decreased phosphorylation of Stat. As a consequence, Stat
phosphorylation and translocation to nucleus as well as anti-
apoptotic Bcl-2 and Xiap protein expressions were decreased
while increasing Bax thereby activating mitochondrial death
cascade in these cells. The functional consequence is a state of
CD4
+ T cell depletion. Although CD4
+ T cells are central to the
function of the immune system, their role in tumor immunity
remains under-appreciated. Recent advances in understanding of
contribution of CD4
+ in anti-tumor immunity, as well as some
intriguing developments in the clinic, indicate that due to the
cooperative role of CD4
+ helper T cells for CD8
+ cytotoxic T cells,
they have the unrealized potential in tumor eradication. Based on
our observations, we postulate PGE2 as an important factor
responsible for impaired survival signaling in CD4
+ T cells thereby
Figure 6. Re-confirmation of PGE2 as the molecule behind tumor-induced perturbation in CD4
+ T cell survival signaling. A, MCF-7 cells
were treated with theaflavins or celecoxibor transfectedwith Cox-2-siRNA andthe levelsof Cox-2 andGAPDH(internalcontrol)mRNA were determined
by RT-PCR (upper panel). Western blot analysis was performed for the determination of levels of Cox-2 or a-Actin (internal control) proteins (middle
panel). In parallel experiments the amount of tumor-secreted PGE2 in the cell-free supernatant was determined by ELISA (lower panel). B, Purified CD4
+ T
cells were cultured in the presence of media alone or MCF-7-spent media (tumors were either pre-treated with 25 mg/ml theaflavins/3.5 ng/ml PGE2/
50 mM celecoxib or transfected with 300pmole Cox-2-siRNA) for 48 h. Expression levels of IL2Rcc and Bcl-2 as well as phosphorylation status of Jak-3/
-Stat-5 were determined by Western blotting in which a-Actin was used as internal control (upper panel). In parallel experiments, flowcytometric
determination of percent cell death (lower panel) was established. Values are mean6S.E.M. of three independent experiments.
doi:10.1371/journal.pone.0007382.g006
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PGE2 production. In addition, our results demonstrating thea-
flavin-induced protection of IL2Rcc/Jak-3/Stat-5A signaling as
well as survival of CD4
+ T cells from tumor PGE2-insult signify
that these plant polyphenols may have the potency to sustain the
cell mediated immunity of the cancer-bearer that can be utilized
for developing an effective therapy of this deadly disease.
Materials and Methods
Isolation of CD4
+ T cells
Human venous blood from healthy adult volunteers was
collected with informed consent using heparinized syringes. Whole
blood (100 mL) was diluted with 150 mL of RPMI 1640 (Sigma,
St Louis, MO, USA) and then layered in centrifuge tubes onto
120 mL of Histopaque-1077 (Sigma) gradient. After centrifugation
the opaque interface containing lymphocytes was collected,
washed twice in RPMI 1640 and, after complete supernatant
removal, the pellet was re-suspended in PBS supplemented with
0.5% of BSA and 2 mmol/L EDTA. CD4
+ T cells were purified
from total leukocytes by positive selection using anti-CD4 antibody
coated micro-beads (Milteny Biotech) [68]. The purity of the
isolated CD4
+ T cells was determined by flow cytometry and was
routinely .99% CD3
+ and CD4
+, but was negative for CD8.
Cells were cultured in RPMI 1640 (supplemented with 10 U/ml
recombinant IL-2, 10% fetal bovine serum, 2 mM L-glutamine,
100 mg/ml sodium pyruvate, 100 mM non-essential amino acids,
100 mg/ml streptomycin and 50 U/ml penicillin; Sigma) at 37uC
in humidified incubator containing 5% CO2. Viable cell numbers
were determined by Trypan blue exclusion test. The Jurkat T cell
line (maintained in complete RPMI 1640) and human mammary
epithelial carcinoma cells (MCF-7, MDA-MB-231 and ZR-75-1;
maintained in complete DMEM) were obtained from NCCS,
India. Tumor supernatants freed from cellular components were
used in 1:1 ratio with RPMI to study the effect of tumor
supernatant on CD4
+ T cells.
Tumor cells were pre-treated with different doses of theaflavins
(6.25–50 mg/ml), as per the requirement of the experiment, for
90 min after which the culture media containing extra theaflavins
were replaced by fresh media. Seventy two-hour old cell-free tumor
supernatants were used in 1:1 ratio with RPMI for 48 h to study the
effect of tumor on CD4
+ T/Jurkat cells. To study the role of tumor-
shed PGE2 on CD4
+ T apoptosis, supernatants of Cox-2 inhibitor-
treated (celecoxib; 50 mM) or Cox-2-siRNA-transfected tumor cells
were used. In parallel sets of experiments CD4
+ T cells were
incubated with 3.5 ng/ml of prostaglandin E2 (Sigma).
Plasmid constructs, siRNA and transfections
Flag-tagged (N-terminus) cDNA encoding full length Stat-5A
and Stat-5B, C-terminal truncated Stat-5A (amino acid 713; Stat-
5A713) and Stat-5B (amino acids 718; Stat-5B718) (provided by Dr.
J.N. Ihle of St. Jude Children’s Research Hospital, TN),
constitutively active mutant Stat-5A1*6 (generous gift from Prof.
T. Kitamura, Institute of Medical Science, University of Tokyo,
Japan), Bcl-2, Xiap in Prk5 vector (2 mg/million cells) were
introduced separately into Jurkat T cell using T cell nucleofector
kit (Amaxa, Koein, Germany). Isolation of stably expressing clones
were done by limiting dilution and selection with IL2 (25 U/ml)
and hygromycin B (800 mg/ml) for 14 days and cells surviving this
treatment were cloned and assessed for Bcl-2 and Stat-5
expressions by Western blot analysis. Tumor cells were transfected
with 300pmole of Cox-2-/control-ds-siRNA (Santa Cruz) and
lipofectamine 2000 separately for 12 h. Levels of Cox-2 mRNA
and protein were estimated by RT-PCR and Western blotting.
Transfected cells were cultured for 72 h and cell free supernatants
were collected for subsequent experiments.
Flow cytometry
For the determination of cell death, CD4
+ T cells were labelled
with 7-aminoactinomycin D (7-AAD) and Annexin-V-phycoerythrin
(PE)(BD Bioscience)and analyzedonflowcytometer(FACSCalibur;
Becton Dickinson), equipped with 488 nm Argon laser light source
using CellQuest software. Electronic compensation of the instrument
was done to exclude overlapping of the emission spectra. Total
10,000 events were acquired and cells were properly gated for
analysis. Annexin-V
+/7-AAD
+/CD4
+ cells were regarded as apo-
ptotic cells. To determine the surface levels of IL2Rcce x p r e s s i o n ,
CD4
+ Tc e l l sw e r ei n c u b a t e dw i t ha n t i - I L 2 R cc( 2mg/ml; Santa
Cruz) antibody and then with FITC-conjugated 2nd antibody
followed by flowcytometric analysis.
Co-immunoprecipitation and immunoblotting
Primary human CD4
+ T cells were lysed in buffer (10 mM
Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT)
and nuclei were pelleted by brief-centrifugation. The supernatant
was spun at 105,0006g to get cytosolic fraction. The nuclear
extract was prepared in buffer containing 20 mM HEPES, pH
7.9, 25% (v/v) glycerol, 420 mM KCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, and 0.5 mM PMSF. For whole cell lysate,
cells were homogenized in buffer (20 mM Hepes, pH 7.5, 10 mM
KCl, 1.5 mM MgCl2, 1 mM Na-EDTA and 1 mM DTT). All the
buffers were supplemented with protease and phosphatase
inhibitor cocktails [69,70]. For direct Western blot analysis, cell
lysates or the particular fractions containing 50 mg protein was
separated by SDS-polyacrylamide gel electrophoresis and trans-
ferred to nitrocellulose membrane. The protein of interest was
visualized by chemiluminescence.
For the determination of direct interaction between two proteins,
co-immunoprecipitation technique was employed. The immuno-
purified proteins were then detected by Western blot using specific
antibody (Santa Cruz). Equal protein loading was confirmed by re-
probing the blots with a-actin/histone H1 antibody (Santa Cruz).
Prostaglandin E2 assay
PGE2 content in culture supernatants was determined using
PGE2 ELIZA bioassay kit (US Biologicals) following the
manufacturer’s protocol.
Statistical Analysis
Values are shown as standard error of mean (SEM) except
otherwise indicated. Comparison of multiple experimental groups
was performed by 2-way ANOVA followed by a post-hoc
Bonferroni multiple comparison test. Data were analyzed and,
when appropriate, significance of the differences between mean
values was determined by a Student’s t test. Results were
considered significant at p,0.05.
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